SCHEMBL23973005

SCHEMBL23973005

O=c1[nH]c(C2(c3ccccc3)CC2)nc2c1CCNCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.54
OPRM1 P35372 1/20 0.41
TNKS O95271 3/20 0.39
TNKS2 Q9H2K2 3/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.37
CYP2C9 P11712 1/20 0.37
DAO P14920 1/20 0.37
HTR2A P28223 2/20 0.36
PKM P14618 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTR2B P41595 3/20 0.35
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
HTR7 P34969 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26602843 0.99 HTR2C (0.53) HTR2COPRM1TNKSTNKS2KMT2A
SCHEMBL23972481 0.91 HTR2C (0.44) HTR2COPRM1TNKSTNKS2KMT2A
SCHEMBL23973136 0.91 HTR2C (0.44) HTR2COPRM1TNKSTNKS2KMT2A
SCHEMBL23973129 0.86 HTR2C (0.43) HTR2COPRM1TNKSTNKS2KMT2A
SCHEMBL23973342 0.84 HTR2C (0.42) HTR2CTNKSTNKS2KMT2AHTR2A
SCHEMBL23972365 0.84 HPGD (0.38) HTR2COPRM1TNKSTNKS2KMT2A
SCHEMBL23972370 0.84 HPGD (0.38) HTR2COPRM1TNKSTNKS2KMT2A
SCHEMBL23973332 0.81 MAPT (0.41) HTR2CTNKSTNKS2KMT2AALDH1A1
SCHEMBL23972388 0.81 DAO (0.38) HTR2COPRM1TNKSTNKS2KMT2A
Hydrochloric Acid SCHEMBL26602820 0.80 DAO (0.38) HTR2COPRM1TNKSTNKS2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115427409-B Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2025-02-25 CN claimed
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
CN-115427409-B Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2025-02-25 CN disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
CN-115776890-A TRPV4 inhibitors as therapeutic agents for eye diseases 拉夸里亚创药株式会社 2023-03-10 CN disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 HTR2C 123/4885OPRM1 204/4885TNKS 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.